{"prompt": "['2016N298481_02', 'CONFIDENTIAL', '205270', '12.2.2.', 'Financial Disclosure', 'Investigators and sub-investigators will provide the sponsor with sufficient, accurate', 'financial information as requested to allow the sponsor to submit complete and accurate', 'financial certification or disclosure statements to the appropriate regulatory authorities.', 'Investigators are responsible for providing information on financial interests during the', 'course of the study and for 1 year after completion of the study.', '12.2.3.', 'Informed Consent Process', 'The investigator or his/her representative will explain the nature of the study to', 'the participant or his/her legally authorized representative and answer all', 'questions regarding the study.', 'Participants must be informed that their participation is voluntary. Participants or', 'their legally authorized representative will be required to sign a statement of', 'informed consent that meets the requirements of 21 CFR 50, local regulations,', 'ICH guidelines, Health Insurance Portability and Accountability Act (HIPAA)', 'requirements, where applicable, and the IRB/IEC or study center.', 'The medical record must include a statement that written informed consent was', 'obtained before the participant was enrolled in the study and the date the written', 'consent was obtained. The authorized person obtaining the informed consent', 'must also sign the ICF.', 'Participants must be re-consented to the most current version of the ICF(s)', 'during their participation in the study.', \"A copy of the ICF(s) must be provided to the participant or the participant's\", 'legally authorized representative.', 'Participants who are rescreened are required to sign a new ICF.', '12.2.4.', 'Data Protection', 'Participants will be assigned a unique identifier by the sponsor. Any participant', 'records or datasets that are transferred to the sponsor will contain the identifier', 'only; participant names or any information which would make the participant', 'identifiable will not be transferred.', 'The participant must be informed that his/her personal study-related data will be', 'used by the sponsor in accordance with local data protection law. The level of', 'disclosure must also be explained to the participant.', 'The participant must be informed that his/her medical records may be examined', 'by Clinical Quality Assurance auditors or other authorized personnel appointed', 'by the sponsor, by appropriate IRB/IEC members, and by inspectors from', 'regulatory authorities.', '12.2.5.', 'Quality Control (Study Monitoring)', 'In accordance with applicable regulations including GCP, and GSK procedures, GSK', 'monitors will contact the site prior to the start of the study to review with the site staff', '78']['2016N298481_0', 'CONFIDENTIAL', '205270', 'the protocol, study requirements, and their responsibilities to satisfy regulatory,', 'ethical, and GSK requirements.', 'When reviewing data collection procedures, the discussion will also include', 'identification, agreement and documentation of data items for which the eCRF will', 'serve as the source document.', 'GSK will monitor the study and site activity to verify that the:', 'Data are authentic, accurate, and complete.', 'Safety and rights of subjects are being protected.', 'Study is conducted in accordance with the currently approved protocol and any other', 'study agreements, GCP, and all applicable regulatory requirements.', 'The investigator and the head of the medical institution (where applicable) agrees to', 'allow the monitor direct access to all relevant documents', '12.2.6.', 'Data Quality Assurance', 'All participant data relating to the study will be recorded on printed or electronic', 'CRF unless transmitted to the sponsor or designee electronically (e.g.,', 'laboratory data). The investigator is responsible for verifying that data entries', 'are accurate and correct by physically or electronically signing the CRF.', 'The investigator must maintain accurate documentation (source data) that', 'supports the information entered in the CRF.', 'The investigator must permit study-related monitoring, audits, IRB/IEC review,', 'and regulatory agency inspections and provide direct access to source data', 'documents.', 'In the event of an assessment, audit or inspection, the investigator (and', 'institution) must agree to grant the advisor(s), auditor(s) and inspector(s) direct', 'access to all relevant documents and to allocate their time and the time of their', 'staff to discuss the conduct of the study, any findings/relevant issues and to', 'implement any corrective and/or preventative actions to address any', 'findings/issues identified.', 'The sponsor or designee is responsible for the data management of this study', 'including quality checking of the data.', 'Study monitors will perform ongoing source data verification to confirm that', 'data entered into the CRF by authorized site personnel are accurate, complete,', 'and verifiable from source documents; that the safety and rights of participants', 'are being protected; and that the study is being conducted in accordance with the', 'currently approved protocol and any other study agreements, ICH GCP, and all', 'applicable regulatory requirements.', 'Records and documents, including signed ICF, pertaining to the conduct of this', 'study must be retained by the investigator for 25 years from the issue of the final', '79']\n\n###\n\n", "completion": "END"}